David A. Siegel Bluebird Bio, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 713,100 shares of BLUE stock, worth $213,930. This represents 0.0% of its overall portfolio holdings.

Number of Shares

713,100

Previous 846,200 15.73%

Holding current value

$213,930

Previous $829,000 55.37%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.47 - $1.35 $62,557 - $179,685	-133,100 Reduced 15.73%	713,100 $370,000
Q2 2024 Aug 14, 2024	SELL	$0.85 - $1.26 $267,410 - $396,396	-314,600 Reduced 27.1%	846,200 $829,000
Q1 2024 May 15, 2024	BUY	$0.91 - $1.75 $720,902 - $1.39 Million	792,200 Added 214.92%	1,160,800 $1.49 Million
Q4 2023 Feb 14, 2024	BUY	$1.32 - $4.83 $486,552 - $1.78 Million	368,600 New	368,600 $508,000
Q4 2022 Feb 14, 2023	SELL	$5.77 - $8.49 $5,770 - $8,490	-1,000 Reduced 3.18%	30,400 $210,000
Q3 2022 Nov 14, 2022	SELL	$3.75 - $7.39 $791,250 - $1.56 Million	-211,000 Reduced 87.05%	31,400 $199,000
Q3 2022 Nov 14, 2022	SELL	$3.75 - $7.39 $791,250 - $1.56 Million	-211,000 Reduced 87.05%	31,400 $199,000
Q2 2022 Aug 15, 2022	SELL	$2.94 - $5.23 $884,352 - $1.57 Million	-300,800 Reduced 55.38%	242,400 $1 Million
Q1 2022 May 16, 2022	BUY	$4.07 - $10.6 $1.91 Million - $4.98 Million	469,800 Added 640.05%	543,200 $2.64 Million
Q4 2021 Feb 14, 2022	BUY	$8.96 - $16.31 $657,664 - $1.2 Million	73,400 New	73,400 $733,000
Q2 2021 Aug 16, 2021	SELL	$18.04 - $22.09 $1.24 Million - $1.51 Million	-68,500 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$16.59 - $33.89 $1.79 Million - $3.66 Million	-107,900 Reduced 61.17%	68,500 $2.07 Million
Q4 2020 Feb 16, 2021	SELL	$27.5 - $37.92 $1.81 Million - $2.49 Million	-65,700 Reduced 27.14%	176,400 $7.63 Million
Q3 2020 Nov 16, 2020	BUY	$34.44 - $43.75 $3.83 Million - $4.87 Million	111,200 Added 84.95%	242,100 $13.1 Million
Q2 2020 Aug 14, 2020	BUY	$27.12 - $45.97 $509,856 - $864,236	18,800 Added 16.77%	130,900 $7.99 Million
Q1 2020 May 15, 2020	SELL	$26.16 - $63.5 $10,464 - $25,400	-400 Reduced 0.36%	112,100 $5.15 Million
Q4 2019 Feb 14, 2020	BUY	$46.96 - $61.67 $5.28 Million - $6.94 Million	112,500 New	112,500 $9.87 Million
Q1 2019 May 15, 2019	SELL	$64.44 - $104.11 $2.85 Million - $4.6 Million	-44,200 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$59.1 - $93.26 $2.61 Million - $4.12 Million	44,200 New	44,200 $4.39 Million
Q2 2018 Aug 14, 2018	SELL	$99.64 - $127.59 $25 Million - $32.1 Million	-251,200 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$105.8 - $150.94 $22.4 Million - $31.9 Million	-211,300 Reduced 45.69%	251,200 $42.9 Million
Q4 2017 Feb 14, 2018	BUY	$81.25 - $130.7 $36.4 Million - $58.5 Million	447,600 Added 3004.03%	462,500 $82.4 Million
Q3 2017 Nov 14, 2017	BUY	$57.74 - $91.42 $860,326 - $1.36 Million	14,900	14,900 $2.05 Million

Others Institutions Holding BLUE

# of Institutions

151

Shares Held

63.4M

Call Options Held

264K

Put Options Held

428K

View Full List

About bluebird bio, Inc.

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $23.1M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

More about BLUE

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account